<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2804">
  <stage>Registered</stage>
  <submitdate>28/05/2010</submitdate>
  <approvaldate>28/05/2010</approvaldate>
  <nctid>NCT01139138</nctid>
  <trial_identification>
    <studytitle>Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer</studytitle>
    <scientifictitle>A Phase IB/II Study of Second Line Therapy With Panitumumab, Irinotecan and Everolimus (PIE) in Metastatic Colorectal Cancer With KRAS WT</scientifictitle>
    <utrn />
    <trialacronym>PIE</trialacronym>
    <secondaryid>AU-2009-0003/CRAD001CAU06T</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Colorectal Cancer</healthcondition>
    <healthcondition>Colorectal Carcinoma</healthcondition>
    <healthcondition>Colorectal Tumors</healthcondition>
    <healthcondition>Neoplasms, Colorectal</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Panitumumab
Treatment: drugs - Irinotecan
Treatment: drugs - Everolimus

Experimental: Panitumumab + Irinotecan + Everolimus - 


Treatment: drugs: Panitumumab
Panitumumab 6mg/kg IV every 14 days

Treatment: drugs: Irinotecan
Irinotecan 200mg/m2 IV every 14 days

Treatment: drugs: Everolimus
Everolimus daily po (dosage varies with cohort)

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Dose limiting toxicities - To determine the maximum tolerated dose (MTD)of everolimus, irinotecan and panitumumab when given in combination for patients with Kras WT mCRC</outcome>
      <timepoint>at end of cycle 2 (each cycle is 14 days)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety &amp; toxicity - Safety and toxicity assessed weekly during the phase Ib component (as per NCI CTCAE version 3.0) and fortnightly during the phase II component</outcome>
      <timepoint>Approximately 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Response rate - Objective tumour response as per RECIST criteria V1.0</outcome>
      <timepoint>Assessed every 6 weeks until disease progression</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression free survival</outcome>
      <timepoint>Until disease progression, occurrence of new disease or death</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival</outcome>
      <timepoint>Assessed 3 monthly until death</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Age &gt; 18 years

          -  Histological diagnosis of colorectal cancer that is KRAS wild type

          -  Metastatic disease not amenable to resection

          -  Measurable disease as assessed by CT scan using RECIST criteria

          -  Received and failed fluoropyrimidine therapy

          -  Radiographically documented disease progression per RECIST criteria

          -  For phase 1b group only, ECOG PS 0-1

          -  For phase 2 group only, ECOG PS 0-2

          -  Adequate bone marrow function with haemoglobin &gt; 100 g/L, platelets &gt; 100 X 109/l;
             neutrophils &gt; 1.5 X 109/l within 7 days of enrolment

          -  Adequate renal function, with calculated creatinine clearance &gt;40 ml/min (Cockcroft
             and Gault) within 7 days of enrolment

          -  Adequate hepatic function with serum total bilirubin &lt; 1.25 X upper limit of normal
             range and ALT or AST&lt;2.5xULN (&lt;5xULN if liver metastases present) within 7 days of
             enrolment

          -  Magnesium = lower limit of normal within 7 days of enrolment.

          -  Fasting serum cholesterol = 7.75mmol/L AND fasting triglycerides = 2.5 x ULN. Note: In
             case one or both of these thresholds are exceeded, the patient can only be included
             after initiation of appropriate lipid lowering medication.

          -  Life expectancy of at least 12 weeks

          -  Negative pregnancy test = 72 hours before commencing study treatment (women of
             childbearing potential only).

          -  Written informed consent including consent for biomarker studies</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Presence of KRAS mutation in tumour sample

          -  For Phase 1b group only, patients with prior pelvic radiotherapy.

          -  Systemic chemotherapy, immunotherapy, approved proteins/antibodies or any
             investigational agent within 4 weeks prior to commencing study treatment

          -  Radiotherapy within 14 days of commencing study treatment.

          -  Unresolved toxicities from prior systemic therapy or radiotherapy

          -  Medical or psychiatric conditions that compromise the patient's ability to give
             informed consent or to complete the protocol

          -  Prior treatment with drugs targeting EGFR such as cetuximab, panitumumab or erlotinib

          -  Prior therapy with mTOR inhibitors (sirolimus, temsirolimus, everolimus)

          -  Prior therapy with irinotecan

          -  CYP3A4 enzyme inducing anti-convulsant medication = 14 days prior to study treatment.

          -  Ketoconazole = 7 days before study treatment.

          -  Uncontrolled diabetes mellitus defined by fasting glucose &gt;1.5 x ULN.

          -  Known cirrhosis, chronic active hepatitis, or chronic persistent hepatitis

          -  Patients with known interstitial lung disease or severely impaired lung function

          -  Patients with active bleeding diatheses.

          -  Any uncontrolled clinically significant cardiac disease, arrhythmias or angina
             pectoris

          -  Active inflammatory bowel disease or other bowel disease causing chronic diarrhoea

          -  Chronic treatment with immunosuppressives

          -  Patients with a known history of HIV seropositivity

          -  Patients who have any severe and/or uncontrolled medical conditions or infections

          -  Untreated or symptomatic CNS metastases

          -  Patients who have a history of another primary malignant disease

          -  Pregnancy or lactation.

          -  Women and partners of women of childbearing potential who are not using effective
             contraception.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>49</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/06/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>The Queen Elizabeth Hospital - Adelaide</hospital>
    <postcode>5011 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>The Queen Elizabeth Hospital</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Amgen</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Novartis</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will assess the safety of panitumumab, irinotecan and everolimus when given in
      combination to treat advanced colorectal cancer</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01139138</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Amanda Townsend, MBBS</name>
      <address>Queen Elizabeth Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>